# PeptideScanner evidence objects: Maridebart cafraglutide

Every published version of the records placed with Maridebart cafraglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json. Selected public evidence only; not medical advice.

- Objects: 23
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct06660173-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT06660173

> PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06660173-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-11
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06660173-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06660173-maridebart-cafraglutide-v1
- Content SHA-256: `8d15b4e79c75a97282d34f7b78dcd2612220dc6aed659d65b84739a75c1f3858`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06660173 ([`ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e`](#source-ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e`](#source-ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e`](#source-ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e`](#source-ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e))

### Sources

<a id="source-ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e"></a>
- **ClinicalTrials.gov record NCT06660173 · retained source version 2026-09-11:dfcf2dd8720eee75605fef185ae1153439869797ef1a2e2f6d827aef846b701b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06660173) (`ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06660173." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06660173-maridebart-cafraglutide-v1 SHA-256: 8d15b4e79c75a97282d34f7b78dcd2612220dc6aed659d65b84739a75c1f3858.

---

<a id="clinicaltrials-gov-nct06858839-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT06858839

> PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06858839-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-17
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06858839-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06858839-maridebart-cafraglutide-v1
- Content SHA-256: `d5319106c8efa27c12308bc42a1cd17fd8c9316862afa46880e2d85883588caf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06858839 ([`ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3`](#source-ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3`](#source-ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3`](#source-ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3`](#source-ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3))

### Sources

<a id="source-ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3"></a>
- **ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06858839) (`ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06858839." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06858839-maridebart-cafraglutide-v1 SHA-256: d5319106c8efa27c12308bc42a1cd17fd8c9316862afa46880e2d85883588caf.

---

<a id="clinicaltrials-gov-nct06987695-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT06987695

> PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06987695-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06987695-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06987695-maridebart-cafraglutide-v1
- Content SHA-256: `5a91ff8681233ec7ede0a9b976294754fe49fc0dcaad3aebcf7d7314a3a7a865`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06987695 ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`](#source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965))

### Sources

<a id="source-ctg-observation-nct06987695-2025-12-17-6b02adf2b965"></a>
- **ClinicalTrials.gov record NCT06987695 · retained source version 2025-12-17:6b02adf2b9653a7e1104f8657f56e6753e437be3897ab65b54cbc4c013f2bc18** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06987695) (`ctg-observation-nct06987695-2025-12-17-6b02adf2b965`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06987695." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct06987695-maridebart-cafraglutide-v1 SHA-256: 5a91ff8681233ec7ede0a9b976294754fe49fc0dcaad3aebcf7d7314a3a7a865.

---

<a id="clinicaltrials-gov-nct07037433-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07037433

> PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07037433-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-24
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07037433-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07037433-maridebart-cafraglutide-v1
- Content SHA-256: `7f41469849b715bd4deda9da6f54470b11b435f0c067a82399f5344adb548201`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07037433 ([`ctg-observation-nct07037433-2026-07-24-ae9704758762`](#source-ctg-observation-nct07037433-2026-07-24-ae9704758762))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037433-2026-07-24-ae9704758762`](#source-ctg-observation-nct07037433-2026-07-24-ae9704758762))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037433-2026-07-24-ae9704758762`](#source-ctg-observation-nct07037433-2026-07-24-ae9704758762))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07037433-2026-07-24-ae9704758762`](#source-ctg-observation-nct07037433-2026-07-24-ae9704758762))

### Sources

<a id="source-ctg-observation-nct07037433-2026-07-24-ae9704758762"></a>
- **ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07037433) (`ctg-observation-nct07037433-2026-07-24-ae9704758762`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07037433." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07037433-maridebart-cafraglutide-v1 SHA-256: 7f41469849b715bd4deda9da6f54470b11b435f0c067a82399f5344adb548201.

---

<a id="clinicaltrials-gov-nct07037459-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07037459

> PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07037459-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07037459-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07037459-maridebart-cafraglutide-v1
- Content SHA-256: `26332b63ecd6182595dc26b2444412e9b616f701d33d5aa367b46be43c71a072`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07037459 ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07037459-2026-07-02-199638062a19`](#source-ctg-observation-nct07037459-2026-07-02-199638062a19))

### Sources

<a id="source-ctg-observation-nct07037459-2026-07-02-199638062a19"></a>
- **ClinicalTrials.gov record NCT07037459 · retained source version 2026-07-02:199638062a19e7df645ce1f76202d15ba272ee303ca7769667116afd6858e958** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07037459) (`ctg-observation-nct07037459-2026-07-02-199638062a19`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07037459." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07037459-maridebart-cafraglutide-v1 SHA-256: 26332b63ecd6182595dc26b2444412e9b616f701d33d5aa367b46be43c71a072.

---

<a id="clinicaltrials-gov-nct07225686-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07225686

> PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07225686-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07225686-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07225686-maridebart-cafraglutide-v1
- Content SHA-256: `68f54de41146b78d8031936bba3c399be626f18b343972c2e2c10cfe91b8d071`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07225686 ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

### Sources

<a id="source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d"></a>
- **ClinicalTrials.gov record NCT07225686 · retained source version 2026-06-12:50c5d117af0dc48b2dd50fb0b65e9d36906883af0c94c88c6c3b44d9da0c56f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07225686) (`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07225686." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07225686-maridebart-cafraglutide-v1 SHA-256: 68f54de41146b78d8031936bba3c399be626f18b343972c2e2c10cfe91b8d071.

---

<a id="clinicaltrials-gov-nct07226765-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07226765

> PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07226765-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07226765-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07226765-maridebart-cafraglutide-v1
- Content SHA-256: `f5fd5a6e09be15806d805592c47d27aafd7e71407da29e57ae489110e89f6244`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07226765 ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

### Sources

<a id="source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4"></a>
- **ClinicalTrials.gov record NCT07226765 · retained source version 2026-06-12:7e841bc432b47bbab67050e3d0fad0b2eb875d796eedd4f2f6deedf391de2317** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07226765) (`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07226765." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07226765-maridebart-cafraglutide-v1 SHA-256: f5fd5a6e09be15806d805592c47d27aafd7e71407da29e57ae489110e89f6244.

---

<a id="clinicaltrials-gov-nct07229157-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07229157

> PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07229157-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07229157-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07229157-maridebart-cafraglutide-v1
- Content SHA-256: `f037ec7d162db632a0d0253f247f087a2bf79fded1674378589d218b2cfaa828`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07229157 ([`ctg-observation-nct07229157-2026-01-23-ad418d0b577e`](#source-ctg-observation-nct07229157-2026-01-23-ad418d0b577e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07229157-2026-01-23-ad418d0b577e`](#source-ctg-observation-nct07229157-2026-01-23-ad418d0b577e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07229157-2026-01-23-ad418d0b577e`](#source-ctg-observation-nct07229157-2026-01-23-ad418d0b577e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07229157-2026-01-23-ad418d0b577e`](#source-ctg-observation-nct07229157-2026-01-23-ad418d0b577e))

### Sources

<a id="source-ctg-observation-nct07229157-2026-01-23-ad418d0b577e"></a>
- **ClinicalTrials.gov record NCT07229157 · retained source version 2026-01-23:ad418d0b577ec2136f82a066a578858c0a65ab076199537cdfc170e950808516** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07229157) (`ctg-observation-nct07229157-2026-01-23-ad418d0b577e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07229157." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07229157-maridebart-cafraglutide-v1 SHA-256: f037ec7d162db632a0d0253f247f087a2bf79fded1674378589d218b2cfaa828.

---

<a id="clinicaltrials-gov-nct07310563-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07310563

> PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07310563-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07310563-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07310563-maridebart-cafraglutide-v1
- Content SHA-256: `bfa9b11a14b37cfe6f8db2f0dce82496b6fa604c86d30f1ea6e0fcdda120a009`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07310563 ([`ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee`](#source-ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee`](#source-ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee`](#source-ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee`](#source-ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee))

### Sources

<a id="source-ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee"></a>
- **ClinicalTrials.gov record NCT07310563 · retained source version 2026-10-13:d3d2a53a7deeaaade829d9b50fff5d8d516b8f18546d3e7dfa49786b153d2578** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07310563) (`ctg-observation-nct07310563-2026-10-13-d3d2a53a7dee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07310563." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07310563-maridebart-cafraglutide-v1 SHA-256: bfa9b11a14b37cfe6f8db2f0dce82496b6fa604c86d30f1ea6e0fcdda120a009.

---

<a id="clinicaltrials-gov-nct07313761-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07313761

> PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07313761-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-07
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07313761-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07313761-maridebart-cafraglutide-v1
- Content SHA-256: `d7c2ccb4749ccfa3930367dbb65ba3bb00433d0ca8791b2a6eab7a48c8809d52`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07313761 ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

### Sources

<a id="source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0"></a>
- **ClinicalTrials.gov record NCT07313761 · retained source version 2026-08-07:e83b3d74dfe048cc939dbfd917b586a5a46559f5c3856ba40d9a8b6750899789** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07313761) (`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07313761." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07313761-maridebart-cafraglutide-v1 SHA-256: d7c2ccb4749ccfa3930367dbb65ba3bb00433d0ca8791b2a6eab7a48c8809d52.

---

<a id="clinicaltrials-gov-nct07441252-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07441252

> PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07441252-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07441252-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07441252-maridebart-cafraglutide-v1
- Content SHA-256: `210ca801685ca0c4827090215ff7b38f4f41319160b7a08b7362fb653a31951f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07441252 ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

### Sources

<a id="source-ctg-observation-nct07441252-2026-06-18-204e72018406"></a>
- **ClinicalTrials.gov record NCT07441252 · retained source version 2026-06-18:204e72018406561b9fd2daba448608e487fe397757a26dd95c32fdcdfedd48bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07441252) (`ctg-observation-nct07441252-2026-06-18-204e72018406`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07441252." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07441252-maridebart-cafraglutide-v1 SHA-256: 210ca801685ca0c4827090215ff7b38f4f41319160b7a08b7362fb653a31951f.

---

<a id="clinicaltrials-gov-nct07575399-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07575399

> PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07575399-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-27
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07575399-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07575399-maridebart-cafraglutide-v1
- Content SHA-256: `9d0c3f9000eb2880e1d21020e7f9bacae14c439071aaa07d99cda0c3e33c1c92`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07575399 ([`ctg-observation-nct07575399-2026-08-27-17e49c29ef1e`](#source-ctg-observation-nct07575399-2026-08-27-17e49c29ef1e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07575399-2026-08-27-17e49c29ef1e`](#source-ctg-observation-nct07575399-2026-08-27-17e49c29ef1e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07575399-2026-08-27-17e49c29ef1e`](#source-ctg-observation-nct07575399-2026-08-27-17e49c29ef1e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07575399-2026-08-27-17e49c29ef1e`](#source-ctg-observation-nct07575399-2026-08-27-17e49c29ef1e))

### Sources

<a id="source-ctg-observation-nct07575399-2026-08-27-17e49c29ef1e"></a>
- **ClinicalTrials.gov record NCT07575399 · retained source version 2026-08-27:17e49c29ef1e4495861f7e35505c30761d39180accda58037a2b0a1c450c59f0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07575399) (`ctg-observation-nct07575399-2026-08-27-17e49c29ef1e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07575399." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07575399-maridebart-cafraglutide-v1 SHA-256: 9d0c3f9000eb2880e1d21020e7f9bacae14c439071aaa07d99cda0c3e33c1c92.

---

<a id="clinicaltrials-gov-nct07684144-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07684144

> PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07684144-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-03
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07684144-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07684144-maridebart-cafraglutide-v1
- Content SHA-256: `63ca2c491fa395f3d89f97e92b167c421bd5d67bde1b0943d9719cee831b7c85`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07684144 ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

### Sources

<a id="source-ctg-observation-nct07684144-2026-09-03-55c606c96523"></a>
- **ClinicalTrials.gov record NCT07684144 · retained source version 2026-09-03:55c606c96523ea42d404f5617e5f68a2c197af4f8392d7f3ab505d7bdf0c5e7a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07684144) (`ctg-observation-nct07684144-2026-09-03-55c606c96523`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07684144." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07684144-maridebart-cafraglutide-v1 SHA-256: 63ca2c491fa395f3d89f97e92b167c421bd5d67bde1b0943d9719cee831b7c85.

---

<a id="clinicaltrials-gov-nct07684235-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07684235

> PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07684235-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-04
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07684235-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07684235-maridebart-cafraglutide-v1
- Content SHA-256: `1ebbd7c8cf3dcc0d6caf52f57400c0c9ba3ad3f225b7e1b867e1cba77373bc26`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07684235 ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

### Sources

<a id="source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b"></a>
- **ClinicalTrials.gov record NCT07684235 · retained source version 2026-08-04:8fc86edf161b19dd348d2fed7847cdbde4ce7abb7d1b1d08beb9b11fb77b82de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07684235) (`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07684235." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07684235-maridebart-cafraglutide-v1 SHA-256: 1ebbd7c8cf3dcc0d6caf52f57400c0c9ba3ad3f225b7e1b867e1cba77373bc26.

---

<a id="clinicaltrials-gov-nct07832799-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07832799

> PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07832799-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-22
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07832799-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07832799-maridebart-cafraglutide-v1
- Content SHA-256: `c750131c359b0bae1953a79c5a2f176f4a5b1beb3792928e383ed37e8cbb56fc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07832799 ([`ctg-observation-nct07832799-2026-09-22-8acd78d54982`](#source-ctg-observation-nct07832799-2026-09-22-8acd78d54982))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07832799-2026-09-22-8acd78d54982`](#source-ctg-observation-nct07832799-2026-09-22-8acd78d54982))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07832799-2026-09-22-8acd78d54982`](#source-ctg-observation-nct07832799-2026-09-22-8acd78d54982))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07832799-2026-09-22-8acd78d54982`](#source-ctg-observation-nct07832799-2026-09-22-8acd78d54982))

### Sources

<a id="source-ctg-observation-nct07832799-2026-09-22-8acd78d54982"></a>
- **ClinicalTrials.gov record NCT07832799 · retained source version 2026-09-22:8acd78d54982c34b9c2c8eb6baccb025c928817131c93a9ec1fe078af4604f1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07832799) (`ctg-observation-nct07832799-2026-09-22-8acd78d54982`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07832799." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07832799-maridebart-cafraglutide-v1 SHA-256: c750131c359b0bae1953a79c5a2f176f4a5b1beb3792928e383ed37e8cbb56fc.

---

<a id="clinicaltrials-gov-nct07871409-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07871409

> PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07871409-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07871409-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07871409-maridebart-cafraglutide-v1
- Content SHA-256: `f5d178ea9005640871f0a89ff272e584b8d3d535bec0e05c60dca1828ee85cc4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07871409 ([`ctg-observation-nct07871409-2026-11-09-044f888fca47`](#source-ctg-observation-nct07871409-2026-11-09-044f888fca47))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07871409-2026-11-09-044f888fca47`](#source-ctg-observation-nct07871409-2026-11-09-044f888fca47))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07871409-2026-11-09-044f888fca47`](#source-ctg-observation-nct07871409-2026-11-09-044f888fca47))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07871409-2026-11-09-044f888fca47`](#source-ctg-observation-nct07871409-2026-11-09-044f888fca47))

### Sources

<a id="source-ctg-observation-nct07871409-2026-11-09-044f888fca47"></a>
- **ClinicalTrials.gov record NCT07871409 · retained source version 2026-11-09:044f888fca4724ddbc09c5b974058539200e01bb960cb97ebd6993ba0f3adfdd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07871409) (`ctg-observation-nct07871409-2026-11-09-044f888fca47`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07871409." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07871409-maridebart-cafraglutide-v1 SHA-256: f5d178ea9005640871f0a89ff272e584b8d3d535bec0e05c60dca1828ee85cc4.

---

<a id="clinicaltrials-gov-nct07908316-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07908316

> PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07908316-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07908316-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07908316-maridebart-cafraglutide-v1
- Content SHA-256: `bac1b7fd3f621c7a08bb9271e6bdb278eec245a797f12dba599b5468e8706e61`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07908316 ([`ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5`](#source-ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5`](#source-ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5`](#source-ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5`](#source-ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5))

### Sources

<a id="source-ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5"></a>
- **ClinicalTrials.gov record NCT07908316 · retained source version 2026-11-02:a5d40d2df2f58ff9f08a1c94d622a6e9e412b047c2c782f6eeb000c48062ab20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07908316) (`ctg-observation-nct07908316-2026-11-02-a5d40d2df2f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07908316." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07908316-maridebart-cafraglutide-v1 SHA-256: bac1b7fd3f621c7a08bb9271e6bdb278eec245a797f12dba599b5468e8706e61.

---

<a id="clinicaltrials-gov-nct07921316-maridebart-cafraglutide-v1"></a>

## ClinicalTrials.gov record NCT07921316

> PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07921316-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-06
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07921316-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07921316-maridebart-cafraglutide-v1
- Content SHA-256: `414af34a03e150478fae7efb7bb958ff4a44245e67e5e26dd67371e59de231c6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07921316 ([`ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2`](#source-ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2`](#source-ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2`](#source-ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2`](#source-ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2))

### Sources

<a id="source-ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2"></a>
- **ClinicalTrials.gov record NCT07921316 · retained source version 2026-11-06:6ee6f9853bc2eba93557db7a910d6356824dc3886fac3ed687adc42df6332c92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07921316) (`ctg-observation-nct07921316-2026-11-06-6ee6f9853bc2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07921316." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#clinicaltrials-gov-nct07921316-maridebart-cafraglutide-v1 SHA-256: 414af34a03e150478fae7efb7bb958ff4a44245e67e5e26dd67371e59de231c6.

---

<a id="maritide-bioavailability-study-updated-v1"></a>

## MariTide bioavailability study record updated

> ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.

- Evidence object: `story:maritide-bioavailability-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/maritide-bioavailability-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#maritide-bioavailability-study-updated-v1
- Content SHA-256: `b328c4484505ed689dd9849477dfa71089fd41ca999d1c8b354fc2e6bbe30a76`

### Claims and source pins

#### Headline

MariTide bioavailability study record updated ([`ctg-nct07717814-v1`](#source-ctg-nct07717814-v1))

#### Summary

ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen. ([`ctg-nct07717814-v1`](#source-ctg-nct07717814-v1))

#### Paragraph 1

ClinicalTrials.gov lists the NCT07717814 record under Amgen. Its overall recruitment status was shown as completed when PeptideScanner reviewed the record. ([`ctg-nct07717814-v1`](#source-ctg-nct07717814-v1))

#### Paragraph 2

The registry shows 2026-07-21 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct07717814-v1`](#source-ctg-nct07717814-v1))

### Sources

<a id="source-ctg-nct07717814-v1"></a>
- **Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07717814?a=1&tab=history) (`ctg-nct07717814-v1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "MariTide bioavailability study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#maritide-bioavailability-study-updated-v1 SHA-256: b328c4484505ed689dd9849477dfa71089fd41ca999d1c8b354fc2e6bbe30a76.

---

<a id="pubmed-pmid-41337722-maridebart-cafraglutide-v1"></a>

## PubMed record PMID 41337722

> PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41337722-maridebart-cafraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41337722-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337722-maridebart-cafraglutide-v1
- Content SHA-256: `b9c325d5819f3d2f0dee0f6bfa11e35c072e4dfebb261e7dd8dbea44267d2fcc`

### Claims and source pins

#### Headline

PubMed record PMID 41337722 ([`pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092`](#source-pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092`](#source-pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092`](#source-pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092`](#source-pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092))

### Sources

<a id="source-pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092"></a>
- **PubMed record PMID 41337722 · retained source version 1:2026-03-04:current:f7b75bc790922f4acc4a637f4e9e6977d30ccd90eace9b7c8f65b20018d96633** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41337722/) (`pubmed-observation-pmid-41337722-2026-03-04-f7b75bc79092`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41337722." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337722-maridebart-cafraglutide-v1 SHA-256: b9c325d5819f3d2f0dee0f6bfa11e35c072e4dfebb261e7dd8dbea44267d2fcc.

---

<a id="pubmed-pmid-41337723-maridebart-cafraglutide-v1"></a>

## PubMed record PMID 41337723

> PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41337723-maridebart-cafraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41337723-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337723-maridebart-cafraglutide-v1
- Content SHA-256: `dc62143e5c6096b41f337b121d09e2f73267b105174a2057756791c614a9f1be`

### Claims and source pins

#### Headline

PubMed record PMID 41337723 ([`pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9`](#source-pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9`](#source-pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9`](#source-pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9`](#source-pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9))

### Sources

<a id="source-pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9"></a>
- **PubMed record PMID 41337723 · retained source version 1:2026-03-04:current:5c351ce6cff93daab209f29bef7827712e519f8fe73f2e180bccf42dff33a511** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41337723/) (`pubmed-observation-pmid-41337723-2026-03-04-5c351ce6cff9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41337723." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337723-maridebart-cafraglutide-v1 SHA-256: dc62143e5c6096b41f337b121d09e2f73267b105174a2057756791c614a9f1be.

---

<a id="pubmed-pmid-41337724-maridebart-cafraglutide-v1"></a>

## PubMed record PMID 41337724

> PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41337724-maridebart-cafraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41337724-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337724-maridebart-cafraglutide-v1
- Content SHA-256: `18c6faa8eebda557a09d764d600fda9175aeef65a3dac0c592fb46ec31f0295b`

### Claims and source pins

#### Headline

PubMed record PMID 41337724 ([`pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3`](#source-pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3`](#source-pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3`](#source-pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3`](#source-pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3))

### Sources

<a id="source-pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3"></a>
- **PubMed record PMID 41337724 · retained source version 1:2025-12-03:current:a4eeac53f0c35b4e52f5f0374d742523825106ce3160700deeaa8759f03915dc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41337724/) (`pubmed-observation-pmid-41337724-2025-12-03-a4eeac53f0c3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41337724." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-41337724-maridebart-cafraglutide-v1 SHA-256: 18c6faa8eebda557a09d764d600fda9175aeef65a3dac0c592fb46ec31f0295b.

---

<a id="pubmed-pmid-42592044-maridebart-cafraglutide-v1"></a>

## Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

> PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42592044-maridebart-cafraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42592044-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-42592044-maridebart-cafraglutide-v1
- Content SHA-256: `32b92034afda1af3af6e25573866b5a2fa58797cbc45223840aa81e288f59688`

### Claims and source pins

#### Headline

Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

#### Summary

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

#### Paragraph 1

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

### Sources

<a id="source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671"></a>
- **Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. · retained source version 1:2026-08-13:current:41bdad7796714760059177aeeebb9c4217b2973c075002cc8d757619c91b8b6e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42592044/) (`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/maridebart-cafraglutide.json#pubmed-pmid-42592044-maridebart-cafraglutide-v1 SHA-256: 32b92034afda1af3af6e25573866b5a2fa58797cbc45223840aa81e288f59688.

